Home
Resources
Publications
Combinatory Effect of Fluconazole and FDA-approved Drugs Against Candida Albicans

Combinatory Effect of Fluconazole and FDA-approved Drugs Against Candida Albicans

Yukihiro Kaneko, Hidesuke Fukazawa, Hideaki Ohno, Yoshitsugu Miyazaki

J Infect Chemother. 2013 Dec;19(6):1141-5.

PMID: 23807392

Abstract:

Candida albicans is the primary cause of systemic candidiasis, which has a high mortality rate. Unfortunately, the number of antifungal drugs available for treatment of Candida infections is limited, and there is an urgent need for development of new drugs and alternative therapeutic options. We investigated the combinatory effect of fluconazole (FLCZ) and 640 FDA-approved drugs in vitro. Ten drugs enhanced and 77 drugs attenuated the antifungal activity of FLCZ. Other drugs did not appear to alter the antifungal activity of FLCZ, although 17 drugs displayed potency equivalent to or greater than that of FLCZ. The 10 FLCZ-enhancing drugs included three inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase, whose synergistic activity had been reported previously. However, the antifungal effects of 3 FLCZ enhancers-artesunate, carvedilol, and bortezomib-were previously unknown. In addition, many drugs were found to attenuate the antifungal activity of FLCZ, including 17 cyclooxygenase (COX) inhibitors, 15 estrogen-related agents, vitamin A- and D-related compounds, antihypertensive drugs, and proton pump inhibitors. Although the clinical significance remains to be determined, analyses of molecular events responsible for synergy or antagonism could provide insight into more efficient use of existing antifungals and lead to novel therapies.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP51997514-B	Carvedilol Related Compound D		51997-51-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: